Clorox CO /DE/

The Clorox Company announced its fourth quarter and full fiscal year 2026 results, reporting a 2% net sales decrease for Q4 and a 5% decrease for the full year, impacted by ERP transition effects and acquisition costs, while providing a FY27 outlook with expected organic sales growth.

The Clorox Company announces a simplified operating structure and key executive appointments to enhance execution and accelerate growth.

The Clorox Company announced that Chair and CEO Linda Rendle will step down following the appointment of a successor to focus on her health.

The Clorox Company has successfully closed a public offering of $1.55 billion in senior notes across three tranches maturing in 2031, 2033, and 2036.

The Clorox Company has completed its acquisition of GOJO Industries, integrating the Purell brand and expanding its health and hygiene offerings.

Clorox reported a 1% net sales decrease and a 16% diluted EPS drop for Q2 FY2026, while reaffirming its full-year outlook.

Clorox completes the $2.25 billion acquisition of GOJO Industries and buys out P&G's stake in the Glad business while navigating a flat sales quarter.

Clorox reports a decline in Q2 net earnings and diluted EPS, driven by lower sales and higher costs, while announcing the strategic acquisition of GOJO Industries for $2.25 billion.

Clorox reports a significant 19% drop in net sales and diluted EPS for Q1 FY26, primarily due to ERP system transition impacts and ongoing macroeconomic pressures.

Clorox's Q3 2025 results show a decrease in net sales due to divestitures, but a significant increase in earnings driven by margin expansion and cost savings.

Clorox's second quarter of fiscal year 2025 saw a decrease in net sales but an increase in earnings per share, influenced by divestitures, cyberattack recovery, and cost-saving measures.

Clorox's first quarter of fiscal year 2025 shows significant improvement in sales and earnings, primarily due to recovery from a prior cyberattack and strategic divestitures.

Clorox reported a 190% increase in diluted net earnings per share for fiscal year 2025, driven by higher volume, cost savings, and cyberattack insurance recoveries, despite essentially flat net sales.

Clorox's fiscal year 2024 saw a net sales decrease due to a cyberattack, but the company achieved significant EPS growth through margin recovery and cost management.

Nina Barton, EVP-Chief Growth & Strategy Of of Clorox Co /De/, reported a transaction in 1,681 shares of common stock on July 22, 2026.

Chris T Hyder, EVP-Chief Operating Officer of Clorox Co /De/, reported a transaction in 277 shares of common stock on July 15, 2026.

Stephanie Plaines, a Director at The Clorox Company, acquired deferred stock units through dividend reinvestment and in lieu of director's fees, as reported in a Form 4 filing.

Matthew J. Shattock, a Director at The Clorox Company, reported transactions involving deferred stock units acquired through dividend reinvestment and in lieu of director's fees.

Clorox Director Pierre R. Breber reported transactions involving deferred stock units acquired through dividend reinvestment and in lieu of director's fees.

Clorox Director Pierre R. Breber reported a transaction involving the sale of 5,000 shares of common stock.

The Clorox Company announces its 2025 Annual Meeting of Shareholders, detailing director nominees, executive compensation vote, and auditor ratification.

Clorox reported resilient fiscal year 2025 performance with gross margin expansion and adjusted EPS growth despite cyberattack impacts and macroeconomic uncertainties, while advancing its IGNITE strategy.

Clorox Company announces its annual shareholder meeting to be held virtually on November 20, 2024, with proxy materials accessible online.

Clorox faced operational challenges due to a cyberattack in August 2023 but still managed to achieve double-digit adjusted earnings per share growth while investing in its brands.

Vanguard Capital Management has filed a Schedule 13G reporting a 7.35% beneficial ownership stake in The Clorox Company.

The Vanguard Group filed an amended Schedule 13G for Clorox Co/The, reporting 0% beneficial ownership following an internal realignment.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a passive beneficial ownership of 8.1% of Clorox's common stock as of June 30, 2025.

UBS Group AG has filed an amendment to its Schedule 13G, indicating it no longer holds a reportable beneficial ownership stake in The Clorox Company as of March 31, 2025.

UBS Group AG has disclosed a beneficial ownership of 8.15% in Clorox Co., totaling 10,084,448 shares, as of December 31, 2024, clarifying a previous administrative inclusion.

UBS Asset Management has filed an amended Schedule 13G for The Clorox Company, correcting its reported beneficial ownership to 0.87% due to an inadvertent inclusion of positions from separate reporting entities in its initial filing.